Introduction
============

Esophageal squamous cell carcinoma (ESCC), a major histologic subtype of esophageal cancer, is one of the most common malignancies and ranks as the sixth leading cause of cancer related death in the world [@B1]. ESCC is characterized by its remarkable geographic distribution, with more than half of ESCC cases worldwide occurring in China. Linzhou and the nearby counties in Henan province of Northern China have the highest incidence rate of ESCC in the world [@B2], [@B3]. Similar to other types of cancers, ESCC is a complex disease with a multistep process of genetic alterations, including activation of oncogenes and inactivation of tumor suppressor genes (TSG) [@B4]. Therefore, it is important to better understand the underlying mechanisms by identifying the recurrent genetic changes and characterizing genes involved in the pathogenesis of ESCC.

Downregulation is a common feature of TSG, which can be caused by allele deletion, promoter hypermethylation, histone deacetylation and posttranscriptional silencing by microRNA. Therefore, comparing gene expression profiles between tumor and non-tumor tissues by using cDNA microarray, and characterizing downregulated genes in tumor specimens are useful strategies to identify TSGs. Recently, Affymetrix cDNA microarray has been used to identify deregulated genes between 4 pairs of ESCC tumors and their adjacent non-tumor tissues, and one pair of esophageal dysplasia tissue and adjacent normal tissue. About 200 downregulated genes were identified in ESCC tumors including Rh family, C glycoprotein (*RHCG*). RHCG belongs to the Rhesus (Rh) family and was first identified as Rh blood group antigens in human erythroid cells. The Rh proteins are closely related to the family of ammonia transporter proteins that is characterized by the presence of 12 transmembrane-spanning segments [@B5], [@B6]. Therefore, Rh family proteins fall into two functionally distinct groups: ammonia transporting Rh glycoproteins (RHAG, RHBG, and RHCG) and nontransporting Rh proteins (RHD and RHCE). Erythroid RHD is recognized for its key role in blood group incompatibility (Rh+, Rh-), where Rh- individuals can develop an immune response upon exposure to Rh+ blood [@B7]. The nonerythroid Rh glycoproteins, RHBG and RHCG, as ammonia transporters, are widely expressed in different tissues in which ammonia metabolism is necessary for normal biological functioning, such as kidneys, liver, central nervous system, and gastrointestinal tract [@B8]-[@B12]. While RHCG was reported to be highly expressed in human esophagus, cervix, oral cavity and skin, its physiological functions are not well documented. Accordingly, recent reports found that RHCG was frequently downregulated in primary ESCC and tongue squamous cell carcinoma compared with their corresponding normal mucosa [@B13], [@B14]; however, the effects of RHCG downregulation on cancer development and progression are still not yet explored. In the present study, we evaluated the expression status of RHCG and its promoter methylation in primary ESCCs and ESCC cell lines. Functional assays with RHCG ectopic-expressing or RHCG-silenced ESCC cell lines were performed to characterize the biological effects of RHCG in ESCC tumorigenicity and metastasis, both *in vitro* and *in vivo*. The tumor-suppressive mechanism of RHCG and its potential to be a new biomarker in ESCC were also addressed.

Results
=======

*RHCG* is a novel tumor suppressor gene in human ESCC
-----------------------------------------------------

To identify deregulated genes during ESCC development, Affymetrix cDNA microarray was applied to compare differentially expressed genes between 4 pairs of ESCC tumors and corresponding adjacent non-tumor tissues (\#301, \#327, \#351 and \#363), and one pair of esophageal dysplasia tissue and adjacent normal tissue (\#314) (GSE100942). About 250 deregulated genes were identified and listed in Table [S1](#SM0){ref-type="supplementary-material"}. According to previous reports and functional prediction of these genes, 30 candidates were chosen for further screening in ESCC clinical samples and cell lines, and *RHCG* was selected for subsequent investigations throughout this study. The expression of *RHCG* was dramatically reduced in 4 ESCC tumors compared with their non-tumor tissues, while its expression remained unchanged in dysplasia tissue (Fig. [1](#F1){ref-type="fig"}A). To determine whether downregulation of *RHCG* was a common event in ESCCs, qRT-PCR was performed to compare expression level of *RHCG* in 45 paired ESCC samples (tumor vs. non-tumor tissues). The result showed that expression of *RHCG* was significantly downregulated in tumor tissues compared with adjacent non-tumor tissues (paired *t* test, *P* \< 0.0001; Fig. [1](#F1){ref-type="fig"}B). Compared with their paired non-tumor tissues, downregulation of *RHCG* was detected in 40/45 (88.9%) of ESCC tissues.

To investigate the clinical significance of RHCG expression in ESCC, expression of RHCG was analyzed by immunohistochemistry (IHC) on a tissue microarray (TMA) consisting of 300 paired ESCC and non-tumor specimens (Fig. [1](#F1){ref-type="fig"}C). Almost three quarters of all informative non-tumor samples displayed high RHCG expression level (171/236, 72.5%), whereas its expression was absent in half of the informative tumor samples (126/253, 49.8%; Fig. [1](#F1){ref-type="fig"}D). Non-informative samples including lost samples and unrepresentative samples were not included in data compilation. A clinicopathologic association study based on 253 informative ESCC samples showed that the absence of RHCG expression was significantly associated with presence of invasion (Pearson χ² test, *P* = 0.003), advanced clinical stage (Pearson χ² test, *P* \< 0.001), lymph node metastasis (Pearson χ² test, *P* = 0.038) and poor differentiation (Pearson χ² test, *P* = 0.001; Table [1](#T1){ref-type="table"}). In a Kaplan-Meier survival analysis comparing patients with different RHCG expression levels, high RHCG expression was significantly associated with long survival time (Log-rank test, *P* \< 0.001). Among patients with different RHCG expression levels, increased survival was observed with enhanced RHCG expression (Fig. [1](#F1){ref-type="fig"}E). Patients with tumor expressing high RHCG expression had the longest mean survival time of 39.6 months, whereas those without RHCG expression had the worst prognosis, with a mean overall survival of 25.2 months. Multivariate Cox regression analysis further revealed that loss of RHCG was an independent prognostic marker for the overall survival of ESCC patients (hazard ratio, 0.541; 95% confidence interval, 0.395-0.743; *P* \< 0.001; Table [S2](#SM0){ref-type="supplementary-material"}).

The *RHCG* promoter region is frequently hypermethylated in ESCC
----------------------------------------------------------------

In addition to clinical samples, we have also determined the expression of RHCG by Western blot analysis in 1 immortalized esophageal epithelial cell line (NE1) and 9 ESCC cell lines. The expression of RHCG was found to be absent or downregulated in all ESCC cell lines as compared with NE1 cells (Fig. [2](#F2){ref-type="fig"}A). Since downregulation of TSG in cancer is often associated with epigenetic regulation including promoter hypermethylation and histone deacetylation, we next studied the effects of DNA demethylation and histone acetylation in RHCG expression. EC109 and KYSE180 cells were treated with different concentrations of the DNA methyltransferase inhibitor (5-zaz-dC) or the histone acetylation agents trichostatin A (TSA). qPCR analysis showed a dose-dependent restoration of RHCG expression after demethylation treatment with 5-aza-dC (Fig. [2](#F2){ref-type="fig"}B). Treatment with the histone acetylation agent TSA did not significantly increase the expression level of RHCG, suggesting that DNA methylation, but not histone modification, is involved in RHCG inactivation in ESCC.

To investigate the role of aberrant promoter hypermethylation in RHCG silencing, BGS and MSP were performed to examine the methylation status of the *RHCG* promoter region. A 10 kb sequence directly upstream of the *RHCG* gene was analyzed by CpG Island Searcher (<http://www.cpgislands.com>) and MethPrimer (<http://www.urogene.org/methprimer>) for potential CpG islands. Only one CpG island was predicted by both programs (-193 nt to +77 nt), as shown in Fig. [2](#F2){ref-type="fig"}C. BGS analysis was conducted at this CpG island and found a high density of methylation in ESCC cell lines, especially in the RHCG-absent EC109 and KYSE180 cells. In contrast, methylation was rarely detected in the same CpG sites in the normal esophageal cell line NE1 (Fig. [2](#F2){ref-type="fig"}C). As compared with untreated cells, methylation was significantly reduced in EC109, KYSE30 and KYSE180 cells treated with 5-aza-dC. We have also performed MSP to investigate the methylation status of *RHCG* in the same panel of cell lines. Methylated allele of *RHCG* was detected in EC109 and KYSE180 cell lines, which were negative for the expression of *RHCG*, whereas no methylated allele was observed in NE1 (Fig. [2](#F2){ref-type="fig"}D). These data were highly consistent with the BGS result. Then, we investigated the methylation frequency of *RHCG* promoter in 22 primary ESCC tumors and their paired non-tumor tissues by MSP. Methylation of *RHCG* was detected in 19/22 (86.4%) of the primary ESCCs. In contrast, methylation was only found in 5/22 (22.7%) of the paired non-tumor tissues (Fig. [2](#F2){ref-type="fig"}E). Taken together, these observations strongly suggested that DNA promoter hypermethylation is implicated in *RHCG* inactivation in ESCC.

RHCG has strong tumor suppressive function
------------------------------------------

To investigate whether RHCG possesses tumor suppressive function, EC109 and KYSE180 cells without RHCG expression were stably transduced with lentivirus packaged with either a *RHCG*-expressing vector or an empty vector (EV) control to generate *RHCG*-overexpressing or control cells. Similarly, KYSE520 cells with high RHCG expression were lentivirally transduced with either *RHCG*-specific short hairpin RNA (shRNA) or a non-target control (NTC) to generate cells with RHCG stably repressed (KYSE520 sh*RHCG*-1 or sh*RHCG*-3) or control cells (KYSE520-NTC). Overexpression and knockdown of RHCG were confirmed at both mRNA and protein levels by PCR and Western blotting, respectively (Fig. [3](#F3){ref-type="fig"}A and [3](#F3){ref-type="fig"}B). Tumor suppressive function of RHCG was assessed by foci formation assay, soft agar assay and tumor xenograft experiment. Compared with control cells, *RHCG*-overexpressing cells displayed lower foci formation frequencies (Fig. [3](#F3){ref-type="fig"}C) and reduced colony forming abilities in soft agar (Fig. [3](#F3){ref-type="fig"}D). Conversely, silencing *RHCG* expression revealed an opposing effect (Fig. [3](#F3){ref-type="fig"}C and [3](#F3){ref-type="fig"}D).

To further investigate the *in vivo* tumor suppressive ability of RHCG, *RHCG*-transfected cells and control cells were subcutaneously injected into the right and left dorsal flank of nude mice, respectively. Tumor induced by control cells showed significantly shorter latency and larger mean tumor volume than tumors induced by *RHCG*-expressing cells (Fig. [3](#F3){ref-type="fig"}E, left). In contrast, mice injected with *RHCG*-silenced KYSE520 cells formed much larger tumors than those formed by NTC cells (Fig. [3](#F3){ref-type="fig"}E, right). These results demonstrated that *RHCG* has a strong tumor suppressive ability both *in vitro* and *in vivo*.

*RHCG* suppresses invasion and lymph node metastasis in ESCC
------------------------------------------------------------

As loss of RHCG was significantly associated with tumor invasion and lymph node metastasis in ESCC patients, the effect of *RHCG* on cell motility and tumor metastasis was studied by wound-healing, cell migration and invasion assays. The wound-healing assay showed that *RHCG* could dramatically inhibit tumor cell mobility (Fig. [4](#F4){ref-type="fig"}A). Cell migration and invasion assays also demonstrated that *RHCG*-transfected cells had suppressed cell migration and invasion abilities, as compared with control cells (Fig. [4](#F4){ref-type="fig"}B). Once endogenous *RHCG* was silenced by shRNA, the abilities of cell migration and invasion were significantly increased (Fig. [4](#F4){ref-type="fig"}A and [4](#F4){ref-type="fig"}B).

To further investigate the effect of *RHCG* on tumor metastasis, a lymph node metastasis animal model was performed by injecting *RHCG*-transfected KYSE180 cells into the right hind foot-pad of NOD/SCID mice. Empty vector-transfected cells were used as controls. In the lymph node metastasis model, popliteal lymph nodes, which represent the sentinel lymph node for this model, were examined [@B15]. Swollen popliteal lymph nodes were observed in all 5 mice injected with control cells, which was confirmed by H&E staining. Only 1/5 of mice injected with *RHCG*-KYSE180 cells displayed tumor metastasis (Fig. [4](#F4){ref-type="fig"}C). Conversely, lymph node metastasis was observed in all mice injected with KYSE520-sh*RHCG* cells, whereas 2/5 mice from the control group showed tumor metastasis. In order to minimize the number of mice to be used, two *RHCG*-specific shRNAs treated cells were equally mixed together as KYSE520-sh*RHCG* group for *in vivo* study.

mRNA profiling identifies an altered network in *RHCG*-expressing KYSE180 cells
-------------------------------------------------------------------------------

In an attempt to characterize the molecular mechanism by which *RHCG* inhibits tumor formation and metastasis in ESCC, a genome-wide mRNA expression profiling screen was used to compare gene expression profiles between *RHCG*-overexpressing KYSE180 cells and their control cells. Using a fold change of 1.5, 125 differentially expressed genes were identified, including 67 upregulated genes and 58 downregulated genes (Table [S3](#SM0){ref-type="supplementary-material"}). Further analysis by IPA software identified a significantly altered functional network on the nuclear factor κB (NF-κB) complex (Fig. [5](#F5){ref-type="fig"}A). To confirm whether the deregulated genes were associated with the expression of RHCG, 5 downregulated genes (*AREG1*, *IL1A*, *LAMC2*, *ABCA1* and *MMP1*) and 5 upregulated genes (*CXCL10*, *APOC1*, *ERG1*, *RBMS3* and *SMAD6*) were selected for validation in both *RHCG*-expressing cells (EC109 and KYSE180) and *RHCG*-silenced KYSE520 cells. The results from qRT-PCR indicated that almost all downregulated genes were negatively associated with *RHCG* expression, in particular, a strong inverse correlation was found in *MMP1* expression (Fig. [5](#F5){ref-type="fig"}B). On the other hand, the expression of upregulated genes was positively correlated with *RHCG* expression (Fig. [5](#F5){ref-type="fig"}C). These results indicated that the mRNA expression profiling screening data were reliable.

RHCG suppresses ESCC metastasis via inhibiting NF-κB signaling
--------------------------------------------------------------

As NF-κB complex member p65 has previously been reported to be overexpressed in ESCCs [@B16], and NF-κB/p65 induces the production of MMPs including MMP1, which subsequently orchestrate the malignant phenotype of ESCC [@B17], [@B18], we therefore hypothesize that RHCG may downregulate MMP1 through inhibiting NF-κB signaling to suppress ESCC progression. To demonstrate this hypothesis, we checked the correlation of RHCG, p65 and MMP1 in clinical specimens of ESCC. IHC staining with antibodies of p65 and MMP1 was performed in the same ESCC TMA. A specific correlation between p65 nuclear location and MMP1 expression was observed in the ESCC samples without RHCG expression, while the nuclear translocation of p65 and the expression of MMP1 in the RHCG-expressing cases were rarely observed (Fig. [6](#F6){ref-type="fig"}A). Linear regression analysis was applied to evaluate the correlation between RHCG and nuclear expression of p65, as well as between nuclear p65 and MMP1. A negative correlation was observed between RHCG and nuclear p65 (R^2^ = 0.13; *P* \< 0.0001), while a positive correlation was found between nuclear p65 and MMP1 (R^2^ = 0.21, *P* \< 0.0001, Fig. [6](#F6){ref-type="fig"}B). Clinicopathologic feature studies showed that nuclear expression of p65 and upregulation of MMP1 were significantly associated with advanced clinical stage, lymph node metastasis in ESCC (Table [S4](#SM0){ref-type="supplementary-material"}-S5), and shorter overall survival rate (Fig. [S1](#SM0){ref-type="supplementary-material"}). These observations prompted us to investigate whether RHCG suppresses MMP1 expression via inhibiting NF-κB signaling.

In resting state, NF-κB/p65 protein is inhibited by IκB in the cytoplasm. When IκB is phosphorylated and subsequently degraded, NF-κB/p65 protein will be activated and translocated to the nucleus for target gene regulation. To test whether RHCG suppresses MMP1 expression via inhibition of NF-κB signaling, we detected IκB/p65 complex by Western blotting in RHCG upregulated- and downregulated-cells. Consistent with qRT-PCR result, RHCG could suppress MMP1 expression, while the opposing effect was observed when RHCG was silenced by shRNA (Fig. [6](#F6){ref-type="fig"}C, left). From the whole protein result, we found that RHCG expression could protect IκB from phosphorylation and degradation (Fig. [6](#F6){ref-type="fig"}C, left). Then, we determined the phosphorylated and total IKKα/β in RHCG upregulated- and downregulated-cells, which are the classical upstream regulators of IκB/p65; however, we could not observe any difference in both cell lines (Fig. [S2](#SM0){ref-type="supplementary-material"}A). To explore whether NF-κB/p65 protein translocates to nucleus upon degradation of IκB, we first successfully isolated cytoplasm protein and nucleus protein from the RHCG upregulated- and downregulated- cells, as confirmed by the presence of β-actin and Histone H3 in cytoplasm and nucleus, respectively. The result demonstrated that the active form of NF-κB/p65 in nucleus was significantly decreased in *RHCG*-expressing cells, whereas it was dramatically elevated in *RHCG*-silenced cells, compared with their control cells (Fig. [6](#F6){ref-type="fig"}C, right). A similar result was observed by immunofluorescence staining, where RHCG expression inhibited the nuclear translocation of p65 (Fig. [6](#F6){ref-type="fig"}D, left). To further validate NF-κB/p65 is the downstream target of RHCG, Caffeic Acid Phenethyl Ester (CAPE, Selleckchem), a selective NF-κB inhibitor that suppresses the nuclear import of p65, was applied to block this signaling. The IF staining demonstrated that p65 nuclear translocation was significantly blocked in *RHCG*-silenced cells after treatment with CAPE (Fig. [6](#F6){ref-type="fig"}D, right). Accordingly, CAPE treatment could also inhibit p65 phosphorylation and *MMP1* expression in *RHCG*-silenced cells (Fig. [6](#F6){ref-type="fig"}E). Consequently, CAPE treated *RHCG*-silenced cells showed lower foci formation frequencies (Fig. [S2](#SM0){ref-type="supplementary-material"}B) and reduced colony forming abilities in soft agar (Fig. [S2](#SM0){ref-type="supplementary-material"}C). Meanwhile, the abilities of migration and invasion of *RHCG*-silenced cells were also suppressed after treatment with CAPE (Fig. [6](#F6){ref-type="fig"}F). These results demonstrated that RHCG suppressed MMP1 expression in ESCC cells, which was dependent on NF-κB/p65 signaling (Fig. [7](#F7){ref-type="fig"}).

Discussion
==========

RHCG is an integral membrane protein that belongs to the Rh family and forms homotrimer in plasma membrane. As a member of ammonia transporters, Rh glycoproteins exert important biological and physiological functions in various tissues, e.g., kidneys, liver, brain and gastrointestinal tract [@B5], [@B8]-[@B11], [@B19]. In addition, RHCG is also highly expressed in human squamous epithelia of esophagus, cervix, and oral cavity; however, the biological functions of RHCG in these tissues have not been explored. Recently, downregulation of RHCG was frequently observed in squamous cell carcinoma from esophagus and tongue [@B13], [@B14]. To date, the relationship between inactivation of RHCG and the development of squamous cell carcinoma is still unknown. In the present study, downregulation of RHCG was frequently detected in primary ESCCs, which was significantly associated with invasion (*P* = 0.003), advanced clinical stage (Pearson χ² test, *P* \< 0.001), lymph node metastasis (*P* = 0.038), poor differentiation (*P* = 0.001) and poorer prognosis (*P* \< 0.001). Further study found that promoter hypermethylation played a crucial role in the downregulation of RHCG in ESCCs.

In the present study, we investigated the tumor suppressive function of RHCG by both *in vitro* and *in vivo* functional assays. Ectopic expression of RHCG in ESCC cell lines EC109 and KYSE180 cells could effectively suppress foci formation, colony formation in soft agar, and tumor formation in nude mice, while RHCG silencing in KYSE520 cells could promote these functions. Our clinical correlation study demonstrated that the downregulation of RHCG was significantly associated with ESCC invasion and lymph node metastasis. Since ESCC primarily exhibits metastasis through the lymphatic system [@B20], [@B21], we constructed a lymph node metastasis model to investigate whether RHCG could suppress tumor metastasis in ESCC [@B15]. Both *in vitro* and lymph node metastasis animal model revealed that RHCG could suppress cell migration, invasion and tumor metastasis.

To explore the molecular mechanism(s) underlying the tumor suppressive functions of RHCG, cDNA microarray was applied to identify potential genes and signaling pathways regulated by RHCG by comparing the expression profiles between RHCG- and empty vector-transfected KYSE180 cells. Interestingly, NF-κB signaling activity was inhibited in RHCG-transfected cells. The NF-κB complex comprises a family of transcription factors involved in regulating a wide variety of biological responses. Aberrant or constitutive NF-κB activation has been detected in many human malignancies and this signaling pathway has been seen as an attractive therapeutic target for cancer treatment [@B22]-[@B25]. Recent studies found that NF-κB/p65 promotes tumorigenicity and metastasis of ESCC by up-regulating MMP1 and MMP9 [@B16], [@B18]. Accordingly, high expressions of MMP1 were frequently found in ESCC and were closely associated with advanced TNM stage and lymph node metastasis. A functional study also revealed that ectopic expression of MMP1 promoted tumor growth and metastasis in ESCC [@B18]. Our data showed that the expression of MMP1 was downregulated in RHCG-expressing cells. In addition, our clinical data showed that expression of MMP1 in ESCC tissues was positively correlated with the nuclear translocation of p65, which was significantly associated with advanced clinical stages and the presence of invasion and lymph node metastasis in primary ESCCs. These findings are consistent with a previous report that NF-κB/p65 could directly bind to the promoter of MMP1 and regulate its expression [@B17]. Further molecular study found that downregulation of RHCG could increase the phosphorylation of IκB for its proteasomal degradation and thus, promote the subsequent activation of NF-κB/p65 and nuclear translocation. Once p65 was translocated into the nucleus, it acted as a transcription regulator and up-regulated MMP1 expression. It is still not known, however, which signals were mediated by transmembrane protein RHCG for the phosphorylation of IκB.

Although different treatment strategies have been developed, the survival rate of ESCC patients remains unsatisfactory [@B26]-[@B28]. Therefore, novel risk markers to guide disease management of ESCC patients are required to tailor treatment to improve their prognosis. As downregulation of RHCG has been significantly associated with poorer prognosis of patients with ESCC, RHCG may be one of the novel prognostic biomarkers in ESCC patients. To further validate the potential clinical application value, univariable and multivariable Cox proportional hazard regression analysis was performed to determine whether downregulation of RHCG is an independent factor for predicting prognosis. The result showed that the downregulation of RHCG was an independent factor and the most influential factor in predicting ESCC outcome. In summary, our findings highlighted a prognostic potential of RHCG, which acts as a potent TSG and exerts a pivotal role in inhibiting tumorigenicity and metastasis in ESCC.

Materials and Methods
=====================

Cell lines
----------

Immortalized normal esophageal epithelial cell line NE1 was obtained from Professor George Tsao\'s laboratory (Department of Anatomy, The University of Hong Kong) in 2006. Chinese ESCC cell lines (HKESC1, EC109 and EC9706) and six Japanese ESCC cell lines (KYSE30, KYSE140, KYSE180, KYSE410, KYSE510, and KYSE520) were kindly provided by Professor Srivastava (Department of Pathology, The University of Hong Kong) in 2004. These adherent cells were trypsinized and expanded for 2 to 4 weeks when confluency reached 70% to 80%. Mycoplasma infection was detected by DNA stain and PCR, and contamination was not found in these cell lines.

Primary ESCC specimens
----------------------

Primary ESCC specimens (300 pairs) and their adjacent nontumor esophageal tissues, used for a tissue microarray (TMA), were collected from patients who underwent esophageal resection at Linzhou Cancer Hospital (Henan, China). Forty-five paired ESCC primary/nontumor tissues, used for DNA and RNA extraction, were collected from ESCC patients at Sun Yat-Sen University Cancer Center (Guangzhou, China). None of these patients received preoperative treatment. Histological examination was carried out by pathologists, and diagnosis was made based on the microscopic features of the carcinoma cells. Tumors were graded using the American Joint Committee on Cancer (AJCC)/International Union Against Cancer (UICC) tumor staging system. Informed consent was obtained from all patients before the collection of esophageal specimens, and samples used in this study were approved by the committees for ethical review of research involving human subjects at Zhengzhou University (Zhengzhou, China), and Sun Yat-Sen University (Guangzhou, China).

Animals
-------

The study protocol was approved by and performed in accordance with the Committee of the Use of Live Animals in Teaching and Research at the University of Hong Kong. For*in vivo* tumorigenic experiment, the cell number used for BALB/cAnN-nu (nude) mice subcutaneous injection was 1×10^6^ (EC109 and KYSE180), and 2×10^5^ (KYSE520). Tumor size was measured twice a week, and tumor volumes were calculated as: V (mm^3^) = L×W^2^×0.5. For *in vivo* metastasis assay, each experimental group consisted of five 4-week-old NOD/SCID mice. Briefly, 3×10^5^ cells in 20 µL PBS were injected into the right hind foot-pad of each mouse. All of the mice were euthanized 6 weeks after injection. The right side popliteal lymph nodes were excised and embedded in paraffin.

Tissue microarray construction and immunohistochemistry
-------------------------------------------------------

Three tissue array blocks with 300 paired primary/nontumor samples were constructed. Briefly, H&E stained slides from each case were used as a guide to identify areas representing different stages of the tumor. The tissues were prepared using a tissue arraying instrument (Beecher Instruments, Silver Spring, MD). A 0.6 mm-diameter cylinder of tissue was removed and re-embedded into a predetermined position in a recipient paraffin block. Immunohistochemistry (IHC) staining was performed using the standard streptavidin-biotin-peroxidase complex method. Briefly, paraffin sections were deparaffinized and rehydrated. Slides were heated for antigen retrieval for 15 min in 10 mM citrate (pH 6.0). Sections were incubated with primary antibody at 4°C overnight. EnVision Plus System-HRP (DAB; DAKO) was used according to manufacturer\'s instruction, followed by Mayer\'s hematoxylin counterstaining. Stained slides were imaged on an AperioScanscope® CS imager (Vista, CA). The intensity of positive staining was scored as: 0, negative; 1, weak; 2, moderate; 3, strong. The total score was determined by the following formula: Staining Index (SI) = intensity × positive percentage × 100. According to ROC curve analyses, the optimum cutoff value for p65 and MMP1 was 100, so SI \< 100 was considered low expression, and S ≥ 100 was considered as high expression. Since half of the ESCC samples did not express RHCG, the samples were divided into negative and positive groups; the positive group was subdivided into low expression (SI \< 100) and high expression (SI ≥ 100) groups.

DNA extraction and promoter methylation analysis
------------------------------------------------

Genomic DNA was extracted by phenol-chloroform method followed by bisulfite modification using the EpiTECT Bisulfite Kit (Qiagen). Primers for bisulfite genomic sequencing (BGS) and methylation-specific PCR (MSP) are listed in Table [S6](#SM0){ref-type="supplementary-material"}. For BGS, the template was amplified by PCR for 35 cycles and then cloned into the pGEM-T Easy vector (Promega) and sequenced as individual clones by Beijing Genomics Institute. The sequence data was analyzed by BiQ analyzer (Max Planck Institute). For MSP, the template was amplified by PCR for 35 cycles, and then analyzed by DNA gel electrophoresis. Cell treatment with 5-aza-2\'-deoxycytidine (5-aza-dC) or trichostatin A (TSA) is described in Supplemental Methods.

*In vitro* tumorigenic assays
-----------------------------

Anchorage-dependent growth was assessed by foci formation assay. Briefly, 2×10^3^ cells were seeded in a 6-well plate. Surviving colonies (\>50 cells/colony) were stained with 1% crystal violet (Sigma-Aldrich) and counted after one week. Anchorage-independent growth was assessed by colony formation in soft agar. In brief, 5×10^3^ cells were mixed thoroughly in 0.35% low melting soft agar (BD Biosciences) and were grown in a 6-well plate precoated with 0.5% agar. After two weeks, colonies (≥ 10 cells) were counted under a microscope in 10 fields per well and photographed.

Migration and invasion assays
-----------------------------

Migration and invasion assays were performed in 24-well millicell hanging insert (Millipore) or 24-well BioCoat Matrigel Invasion Chambers (BD Biosciences). In brief, 1×10^5^ cells were seeded to the top chamber and 10% FBS in medium was added to the bottom chamber as a chemoattractant. After 24 h or 48 h incubation, the number of cells that invaded through the membrane (migration) or Matrigel (invasion) was counted in 10 fields and imaged using SPOT imaging software (Nikon).

cDNA microarray analysis
------------------------

Expression profiling of ESCC clinical samples was performed with HG-U133-PLUS 2 (Affymetrix). Altered gene expression patterns of KYSE180-EV and KYSE180-*RHCG* were compared using Affymetrix GeneChip Human Gene 2.0 ST Array. The data were summarized with the Expression Console™ software (Affymetrix), and further analyzed using GeneSpring GX (Affymetrix) and Ingenuity Pathway Analysis (IPA; Ingenuity Systems) software. Differentially expressed transcripts are listed in Table [S1](#SM0){ref-type="supplementary-material"} and Table [S3](#SM0){ref-type="supplementary-material"}. Microarray data are available at <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE100942>.

Statistical analysis
--------------------

Statistical analysis was carried out with SPSS v. 16 (Chicago, IL). Pearson χ² test was used to analyze the association of RHCG expression with clinicopathologic parameters. Kaplan-Meier plot and log-rank test were used for survival analysis. Univariable and multivariable Cox proportional hazard regression models were used to analyze independent prognostic factors. Student *t* test and ANOVA with post hoc test were used for most studies as indicated in the figure legends. The Pearson correlation coefficients and linear regression analysis were used to evaluate the correlation of RHCG, nuclear p65 and MMP1 in the clinical samples. The data are presented as the mean±SD of three independent experiments. The *P* values are denoted as \**P* \< 0.05, and \*\**P* \< 0.001 in all figures.
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Accession code
==============

cDNA microarray data have been submitted to Gene Expression Omnibus (GEO, <http://www.ncbi.nlm.nih.gov/geo/>) under the accession number GSE100942.
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![**Downregulation of RHCG in clinical ESCCs.** (A) RHCG signal was detected by cDNA microarray in four paired ESCC/nontumor samples (\#301, \#327, \#351 and \#363), and one pair of esophageal dysplasia tissue and adjacent normal tissue (\#314). (B) RHCG expression in matched nontumor and ESCC tumor samples (*n* = 45) as detected by qRT-PCR. GAPDH was used as an internal control. The data displayed as average Δ*C*~t~ values. Boxes in the box plot contain the values between the 25^th^ and 75^th^ percentiles. The lines across the boxes indicate the median. (C) Representative IHC staining of RHCG in ESCC tumor and paired nontumor squamous epithelial tissue (Scale bar = 200 µm). (D) Bar chart summary of the distribution of different RHCG expression levels in nontumor versus tumor for all informative cases on the TMA. (E) Kaplan-Meier survival analysis comparing the overall survival time of ESCC patients with different RHCG expression levels. Statistics: B, paired *t* test; E, Kaplan-Meier analysis and log-rank test.](thnov08p0185g001){#F1}

![**RHCG promoter region is frequently hypermethylated in ESCCs.** (A) Measurement of RHCG expression levels in a panel of ESCC cell lines compared with squamous epithelial cell line NE1 by Western blotting. (B) qRT-PCR analysis of RHCG expression after demethylation or histone acetylation treatment with 5-aza-dC or TSA in ESCC cell lines without RHCG expression. (C) High-resolution mapping of the methylation status of individual CpG site in the *RHCG* promoter by BGS in normal cell line NE1 and ESCC cell lines with or without 5-aza-dC treatment. A 270-bp region spanning the CpG island with 24 CpG sites was analyzed. Each CpG site analyzed is shown at the top row as a short vertical bar. The percentage of methylation was determined as percentage of methylated CpGs from 10 to 15 randomly sequenced clones and is displayed in the pie charts. (D-E) Representative MSP analysis of *RHCG* in esophageal cell lines with or without 5-aza-dC treatment, and paired primary ESCCs/nontumor tissues (T, tumor tissue; N, non-tumor tissue; M: methylation; U: unmethylation).](thnov08p0185g002){#F2}

![**RHCG from ESCC cell lines suppresses tumor formation.** Stable overexpression or repression of *RHCG* by lentiviral transduction was confirmed in both genomic and proteomic levels by PCR (A) and Western blotting (B), respectively. (C-D) Representative images and summaries of foci formation (C) and soft agar assays (D) performed in *RHCG*-overexpressed or -repressed cells as compared with their controls. The values indicate the mean±SD of three independent experiments. (E) Representative images of the subcutaneous tumors formed in nude mice following injection of *RHCG*-overexpressed or -repressed clones and their respective controls. Tumor growth curves are summarized in the line chart. The average tumor volume is expressed as the mean±SD of five mice. Statistics: A, C, D and E, Student *t* test. \*, *P*\<0.05; \*\*, *P*\<0.001.](thnov08p0185g003){#F3}

![**RHCG suppresses *in vivo* lymph node metastasis of ESCC.** (A) Representative images of wound healing in *RHCG*-overexpressed or -repressed cells as compared with their controls. (B) Representative images and summary of migration and invasion assays in *RHCG*-overexpressed or -repressed cells as compared with their controls. The values are expressed as the mean±SD of three independent experiments. Scale bar = 200 µm. (C) Representative images of lymph node metastasis formed in NOD/SCID mice injected with *RHCG*-overexpressed or -repressed cells. Black arrow indicates the swollen popliteal lymph node. Lymph nodes invaded by tumor cells were confirmed by H&E staining (Scale bar = 100 µm). The tumor metastasis rate is shown in the table section. Statistics: B, Student *t* test. \*, *P*\<0.05; \*\*, *P*\<0.001.](thnov08p0185g004){#F4}

![**Deregulated genes in RHCG-overexpressed KYSE180 cells** (A) A significantly deregulated NF-κB network in RHCG-KYSE180 cells identified by genome-wide expression profiling and Ingenuity Pathway Analysis (IPA). Genes in green and red indicate under- and over-expressed genes found in RHCG-KYSE180 cells compared to their negative counterparts. Five under- (B) or over-expressed (C) genes in RHCG-KYSE180 cells were selected to confirm their expression in RHCG overexpressed and suppressed cell lines by qRT-PCR. GAPDH was used as an internal control.](thnov08p0185g005){#F5}

![**RHCG suppresses ESCC metastasis via inhibiting NF-κB signaling and MMP1 expression.** (A) IHC staining for RHCG, p65 and MMP1 expression in the clinical ESCC samples. Scale bar = 50 μm. (B) The correlation between nuclear p65 and RHCG or MMP1 expression was detected by IHC staining in TMA containing 300 ESCC samples. Linear regression lines and Pearson correlation significance are shown. (C) Western blot analysis was used to detect whole cell, cytoplasm and nucleus level of NF-κB signaling and MMP1. β-actin was used as loading controls for whole protein and cytoplasm protein, while Histone H3 was used as a loading control for nuclear protein. (D) Representative images of indicated cells detected by immunofluorescent staining with p65 antibody (red color). Nuclei were counterstained with DAPI (blue color). Cells were treated with DMSO (CON) or 2 µM Caffeic acid phenethyl ester (CAPE). Scale bar = 20 μm. (E) The western blotting result showed that CAPE treatment inhibited activation of p65 and the expression of MMP1 in *RHCG*-suppressed KYSE520 cells. (F) Representative images and summary of migration and invasion assays in *RHCG*-repressed cells treated with or without CAPE. The values are expressed as the mean ± SD of three independent experiments. Scale bar = 200 μm. Statistics: B, Pearson correlation coefficients; F, ANOVA with post hoc test. \*, *P*\<0.05; \*\*, *P*\<0.001.](thnov08p0185g006){#F6}

![A schematic diagram illustrating the proposed RHCG-regulated tumor-suppressive mechanism in ESCC tumorigenicity and metastasis.](thnov08p0185g007){#F7}

###### 

Association of RHCG expression with clinicopathologic features in 253 primary ESCCs

  Features                Total   RHCG expression   *P*-value^b^   
  ----------------------- ------- ----------------- -------------- -------------
  Sex                                                              
  Female                  114     61 (53.5%)        53 (46.5%)     
  Male                    139     65 (46.8%)        74 (53.2%)     0.286
  Age, years                                                       
  \<60                    134     67 (50%)          67 (50%)       
  ≥60                     119     59 (49.6%)        60 (50.4%)     0.947
  Differentiation                                                  
  Well/moderate           188     82 (43.6%)        106 (56.4%)    
  Poor                    65      44 (67.7%)        21 (32.3%)     **0.001**
  Invasion                                                         
  Absent                  89      33 (37.1%)        56 (62.9%)     
  Present                 164     93 (56.7%)        71 (43.3%)     **0.003**
  Clinical Stage^a^                                                
  Early stage I-II        161     66 (41%)          95 (59%)       
  Advanced stage III-IV   92      60 (65.2%)        32 (34.8%)     \<**0.001**
  Lymph node metastasis                                            
  Absent                  135     59 (43.7%)        76 (56.3%)     
  Present                 118     67 (55.8%)        51 (44.2%)     **0.038**

^a^AJCC/UICC TNM staging system.

^b^Pearson χ² test.
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